Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the impact of two different default dialysate sodium concentrations on major cardiovascular events and death in adults receiving maintenance haemodialysis for end-stage kidney disease. This pragmatic, cluster-randomised, open-label Phase 4 study compares sodium levels of 137 mmoll and 140 mmoll in real-world dialysis settings across multiple sites globally. Dialysis sites will be randomly assigned to use either a default dialysate sodium concentration of 137 mmoll or 140 mmoll for at least 90% of dialysis sessions. Other aspects of patient care will follow standard local practices. Sites must consent to participate, and individual patients will provide waiver or opt-out consent. The study expects to enroll sites over 5 to 7 years, with each participant followed for approximately 2 to 5 years until the study endpoints are reached. Participants will receive dialysis at their assigned sites with the designated sodium concentration. Researchers will monitor the time to first occurrence of major cardiovascular events or death as the primary outcome. Secondary outcomes include other cardiovascular events and individual components of the composite outcomes. Data collection and patient monitoring will continue throughout the study period, estimated to last around five years per participant.
Actively Recruiting
Researchers are evaluating a new blood test called Avantect to see if it can detect pancreatic cancer early in people aged 50 to 84 who have recently been diagnosed with type 2 diabetes or have elevated blood sugar levels. Pancreatic cancer is very deadly because it is often found too late for surgery, so early detection could improve treatment options. This trial aims to find out if Avantect can identify pancreatic cancer signals before symptoms appear. Participants will have their blood tested using the Avantect device at three scheduled visits over one year. If the test detects pancreatic cancer markers, participants and their doctors will be informed to arrange further imaging scans like MRI or CT to confirm the diagnosis. The study will track participants remotely for three years after consent to monitor any pancreatic cancer diagnosis or mortality through health registries. During the study, participants will provide blood samples and complete anxiety questionnaires at each visit. Researchers will assess the tests accuracy by measuring its sensitivity and specificity after three years. They will also evaluate how well the test predicts cancer presence, the stage of detected cancers, and surgery rates. The study offers free diagnostic testing and includes ongoing safety and health monitoring for all participants.